Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 02/24/2014 (Date of order of final judgment)

Filing Date: February 01, 2013

Keryx Biopharmaceuticals, Inc is an American biopharmaceutical company that develops and commercializes medicines, primarily for chronic kidney diseases.

According to the law firm press release, the Complaint alleges that Defendants mislead investors about the timing and success of Keryx's clinical trial that tested whether the drug perifosine was effective in treating late stage colorectal cancer.

On April 2, 2012, Keryx announced the top-line data from the perifosine X-PECT Phase 3 Clinical Trial. The Company revealed that the trial for refractory advanced colorectal cancer did not meet the primary endpoint of improving overall patient survival versus capecitabine and a placebo. On this disappointing news, Keryx share price plummeted from $4.98 on March 30, 2012 to $1.74 on April 2, 2012 - a decline of roughly 65%.

This case was dismissed by Order of the Court on February 14, 2014.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.